Global One-stop Pharmacy Research CDMO Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global One-stop Pharmacy Research CDMO Market Research Report 2024
A one-stop pharmacy research CDMO refers to a contract development and manufacturing organization that provides a full range of pharmaceutical research services. It provides a package solution from drug discovery, drug development to pre-clinical trial research to accelerate the development process of new drugs.
According to MRAResearch’s new survey, global One-stop Pharmacy Research CDMO market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole One-stop Pharmacy Research CDMO market research.
A one-stop pharmacy research CDMO usually covers the following servicesdrug discovery, pharmacological research, drug formulation development, synthesis and analytical method development, adverse event reporting and monitoring, pre-clinical trial research, GMP manufacturing. By providing a full range of pharmaceutical research services, the one-stop pharmacy research CDMO can help pharmaceutical companies shorten the R&D cycle, reduce R&D costs, improve product quality, and provide integrated solutions to provide comprehensive support for the R&D work of pharmaceutical companies.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global One-stop Pharmacy Research CDMO market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Medicilon
Gliead
Boehringer Ingelheim
Vertex
Mirati Therapeutics
AMPAC
Pfizer
Polypeptide
Bachem
Merck
Asymchem
Zhejiang Langhua Pharmaceutical
Viva Biotech
Zhejiang Jiuzhou Pharmaceutical
Shanghai Porton Zhihui Biopharmaceutical
Boji Pharmaceutical Technology
GenScript ProBio
Asymchem Laboratories (Tianjin)
Beijing Sun-novo Pharmaceutical Research
Arthur Pharma
Segment by Type
API+Preparation
API+Intermediate+Preparation
Innovative Drugs
Generic Drugs
Improved Drugs
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The One-stop Pharmacy Research CDMO report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global One-stop Pharmacy Research CDMO market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole One-stop Pharmacy Research CDMO market research.
A one-stop pharmacy research CDMO usually covers the following servicesdrug discovery, pharmacological research, drug formulation development, synthesis and analytical method development, adverse event reporting and monitoring, pre-clinical trial research, GMP manufacturing. By providing a full range of pharmaceutical research services, the one-stop pharmacy research CDMO can help pharmaceutical companies shorten the R&D cycle, reduce R&D costs, improve product quality, and provide integrated solutions to provide comprehensive support for the R&D work of pharmaceutical companies.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global One-stop Pharmacy Research CDMO market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Medicilon
Gliead
Boehringer Ingelheim
Vertex
Mirati Therapeutics
AMPAC
Pfizer
Polypeptide
Bachem
Merck
Asymchem
Zhejiang Langhua Pharmaceutical
Viva Biotech
Zhejiang Jiuzhou Pharmaceutical
Shanghai Porton Zhihui Biopharmaceutical
Boji Pharmaceutical Technology
GenScript ProBio
Asymchem Laboratories (Tianjin)
Beijing Sun-novo Pharmaceutical Research
Arthur Pharma
Segment by Type
API+Preparation
API+Intermediate+Preparation
Segment by Application
Innovative Drugs
Generic Drugs
Improved Drugs
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The One-stop Pharmacy Research CDMO report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source